Drug Trial Radar · NCT07068958
A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Nov 1, 2025
Study completion Nov 1, 2025
Sponsor
- Lead sponsor
- ORA, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution twice a day (BID) and four times a day (QID) compared to placebo (vehicle) in the treatment of the signs and symptoms of dry eye. The secondary objective of this study is to evaluate the optimal dosing frequency of 0.25% RCI001 Ophthalmic Solution (BID versus QID) in the treatment of the signs and symptoms of dry eye.
Conditions
- Dry Eye Disease (DED)
Interventions
0.25% RCI001 Ophthalmic SolutionDrug
0.25% RCI001 Ophthalmic Solution
Placebo Ophthalmic Solution (vehicle)Drug
Placebo Ophthalmic Solution (vehicle)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Corneal staining sign measured with the Ora Calibra® Corneal and Conjunctival Staining Scale, and Ocular Discomfort symptom measured with Ora Calibra® Ocular Discomfort Scale in subjects dosed with 0.25% RCI001 Ophthalmic Solution BID, QID or PlaceboTime frame: 4 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.